These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 9617787)
41. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies]. Friedman A Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191 [TBL] [Abstract][Full Text] [Related]
42. Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. Obermann M; Küper M; Kastrup O; Yaldizli O; Esser S; Thiermann J; Koutsilieri E; Arendt G; Diener HC; Maschke M; J Neurol; 2009 Jun; 256(6):948-53. PubMed ID: 19240951 [TBL] [Abstract][Full Text] [Related]
43. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. Durso R; Evans JE; Josephs E; Szabo GK; Evans BA; Handler JS; Jennings D; Browne TR Ann Neurol; 1997 Sep; 42(3):300-4. PubMed ID: 9307250 [TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration. Kanemaru K; Mitani K; Yamanouchi H Neurosci Lett; 1998 Apr; 245(2):121-2. PubMed ID: 9605500 [TBL] [Abstract][Full Text] [Related]
45. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Tohgi H; Abe T; Takahashi S; Takahashi J; Hamato H Neurosci Lett; 1993 Sep; 159(1-2):135-8. PubMed ID: 7505410 [TBL] [Abstract][Full Text] [Related]
46. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Buhmann C; Arlt S; Kontush A; Möller-Bertram T; Sperber S; Oechsner M; Stuerenburg HJ; Beisiegel U Neurobiol Dis; 2004 Feb; 15(1):160-70. PubMed ID: 14751781 [TBL] [Abstract][Full Text] [Related]
47. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat. Mignot E; Laude D; Elghozi JL J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472 [TBL] [Abstract][Full Text] [Related]
48. [Pathomechanism of dyskinesia associated with treatment of Parkinson disease with levodopa]. Friedman A Neurol Neurochir Pol; 1981; 15(4):407-9. PubMed ID: 6173792 [TBL] [Abstract][Full Text] [Related]
49. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
50. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Le WD; Rowe DB; Jankovic J; Xie W; Appel SH Arch Neurol; 1999 Feb; 56(2):194-200. PubMed ID: 10025424 [TBL] [Abstract][Full Text] [Related]
51. CSF homovanillic acid: an index of dopaminergic activity. Curzon G Adv Neurol; 1975; 9():349-57. PubMed ID: 125031 [TBL] [Abstract][Full Text] [Related]
52. Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites. Muthane UB; Satishchandra P; Subhash MN Mov Disord; 1993 Jul; 8(3):344-8. PubMed ID: 7688076 [TBL] [Abstract][Full Text] [Related]
54. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224 [TBL] [Abstract][Full Text] [Related]
55. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; De Bustos F; Zurdo M; Gómez-Escalonilla C; Barcenilla B; Berbel A; Camacho A; Arenas J J Neural Transm (Vienna); 2000; 107(4):445-9. PubMed ID: 11215755 [TBL] [Abstract][Full Text] [Related]
56. Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. Isobe C; Abe T; Kikuchi T; Murata T; Sato C; Terayama Y Eur J Neurol; 2006 Apr; 13(4):346-50. PubMed ID: 16643311 [TBL] [Abstract][Full Text] [Related]
57. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats. Onzawa Y; Kimura Y; Uzuhashi K; Shirasuna M; Hirosawa T; Taogoshi T; Kihira K Biol Pharm Bull; 2012; 35(8):1244-8. PubMed ID: 22863920 [TBL] [Abstract][Full Text] [Related]
58. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Olanow CW; Gauger LL; Cedarbaum JM Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185 [TBL] [Abstract][Full Text] [Related]
59. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. Lloyd KG; Davidson L; Hornykiewicz O J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489 [TBL] [Abstract][Full Text] [Related]